Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
Yu Rebecca MiaoKaushik N ThakkarJin QianMihalis S KariolisWei HuangSaravanan NandagopalTeddy Tat Chi YangAnh N DiepGerald Maxwell CherfYu XuEui Jung MoonYiren XiaoHaizea AlemanyTiane LiWenhua YuBo WeiErinn B RankinAmato J GiacciaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The data presented in this study provide justification for using a dual targeting, high-affinity sPD-1 receptor as an alternative to PD-1 or PD-L1 therapeutic antibodies for achieving superior therapeutic efficacy in cancers expressing both PD-L2 and PD-L1.